Streetbeat News

NRXP

NRx Pharmaceuticals, Inc.

https://www.nrxpharma.com

Industry

Biotechnology

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Open

2.09

Mkt cap

40M

Volume

242K

High

2.40

P/E Ratio

-1.11

52-wk high

6.01

Low

2.08

Div yield

N/A

52-wk low

1.10

NRXP, PDEX, and PBYI have been identified as top momentum stocks by Zacks Rank #1 (Strong Buy) for January 6, 2024.

Portfolio Pulse from

January 06, 2025 | 4:45 pm

HOPE Therapeutics and NRx Pharmaceuticals have signed a binding term sheet for $27 million in funding. This includes $25 million in Series A Preferred Stock for HOPE Therapeutics, convertible into equity, with a 15% dividend, to support clinic acquisitions and NRx operations.

Portfolio Pulse from

January 06, 2025 | 3:30 pm

HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, plans to acquire Dura Medical to establish a network of interventional psychiatry clinics in Florida. This acquisition is expected to boost NRx's revenue and EBITDA.

Portfolio Pulse from

January 06, 2025 | 1:30 pm

Hope Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), plans to acquire Kadima Neuropsychiatry Institute to establish an international network of interventional psychiatry clinics. This acquisition is expected to be immediately accretive to NRx's revenue and EBITDA.

Portfolio Pulse from

January 02, 2025 | 1:30 pm

NRx Pharmaceuticals, Inc. has filed the initial section of a New Drug Application with the FDA for NRX-100, an IV Ketamine treatment for suicidal depression. The company aims to complete the NDA filing by Q1 2025 and will participate in the J.P. Morgan Healthcare Conference in January 2025.

Portfolio Pulse from

December 30, 2024 | 1:15 pm

NRx Pharmaceuticals (NRXP) has been upgraded to a Zacks Rank #2 (Buy), indicating increased optimism about its earnings prospects, which could lead to a rise in its stock price.

Portfolio Pulse from

November 27, 2024 | 6:15 pm

NRx Pharmaceuticals (NASDAQ: NRXP) will participate in the NobleCon20 conference, where Dr. Jonathan Javitt will present. This event could provide insights into the company's growth and future prospects.

Portfolio Pulse from

November 26, 2024 | 1:15 pm

NRx Pharmaceuticals has published a paper in the American Journal of Clinical Psychopharmacology detailing a new training and monitoring methodology that improves interrater reliability in depression ratings for clinical trials. This has positive implications for future trials of NRX-101 and similar medications.

Portfolio Pulse from

November 25, 2024 | 1:15 pm

NRx Pharmaceuticals, Inc. (NRXP) held its Q3 2024 earnings call, discussing financial results and leadership changes. Key participants included Matthew Duffy, Jonathan Javitt, Richard Narido, and Michael Abrams.

Portfolio Pulse from

November 19, 2024 | 1:00 am

NRx Pharmaceuticals has appointed Michael Abrams as its new Chief Financial Officer, replacing interim-CFO Richard Narido, who will now focus on acquisition opportunities for HOPE Therapeutics.

Portfolio Pulse from

November 18, 2024 | 9:15 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.